0001562180-22-007011.txt : 20221004 0001562180-22-007011.hdr.sgml : 20221004 20221004174907 ACCESSION NUMBER: 0001562180-22-007011 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221004 DATE AS OF CHANGE: 20221004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katkin Keith CENTRAL INDEX KEY: 0001314596 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 221293416 MAIL ADDRESS: STREET 1: C/O UROVANT SCIENCES, INC. STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-09-30 false 0001395937 Syndax Pharmaceuticals Inc SNDX 0001314596 Katkin Keith C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM MA 02451 true false false false Common Stock 2022-09-30 4 M false 2914.00 7.88 A 34914.00 D Common Stock 2022-09-30 4 S false 2914.00 25.0707 D 32000.00 D Common Stock 2022-09-30 4 M false 647.00 8.93 A 32647.00 D Common Stock 2022-09-30 4 S false 647.00 25.0707 D 32000.00 D Common Stock 2022-10-03 4 M false 167.00 7.88 A 32167.00 D Common Stock 2022-10-03 4 S false 167.00 25.00 D 32000.00 D Common Stock 2022-10-03 4 M false 13.00 8.93 A 32013.00 D Common Stock 2022-10-03 4 S false 13.00 25.00 D 32000.00 D Common Stock 2022-10-04 4 M false 137.00 7.88 A 32137.00 D Common Stock 2022-10-04 4 S false 137.00 25.00 D 32000.00 D Common Stock 2022-10-04 4 M false 223.00 8.93 A 32223.00 D Common Stock 2022-10-04 4 S false 223.00 25.00 D 32000.00 D Stock Options (Right to buy) 8.93 2022-09-30 4 M false 647.00 0.00 D 2028-05-23 Common Stock 647.00 0.00 D Stock Options (Right to buy) 7.88 2022-09-30 4 M false 2914.00 0.00 D 2029-06-10 Common Stock 2914.00 0.00 D Stock Options (Right to buy) 8.93 2022-10-03 4 M false 13.00 0.00 D 2028-05-23 Common Stock 13.00 0.00 D Stock Options (Right to buy) 7.88 2022-10-03 4 M false 167.00 0.00 D 2029-06-10 Common Stock 167.00 0.00 D Stock Options (Right to buy) 8.93 2022-10-04 4 M false 223.00 0.00 D 2028-05-23 Common Stock 223.00 0.00 D Stock Options (Right to buy) 7.88 2022-10-04 4 M false 137.00 0.00 D 2029-06-10 Common Stock 137.00 0.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. The sale prices ranged from $25.00 to $25.215. The sale price was $25.00. This option is fully vested. /s/ Michael A. Metzger, as Attorney-in-Fact 2022-10-04